^
Association details:
| Biomarker: | AKT1 mutation + ER positive |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Truqap (capivasertib) (AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Published date:
09/10/2020
Excerpt:
Participants were women (aged ≥18 years) with histologically confirmed advanced breast cancer...cohort C comprised patients with AKT1 mutations and oestrogen receptor-positive cancer (treated with oral capivasertib 400 mg plus intramuscular standard-dose fulvestrant)...18 (60%) of 30 patients with an AKT1 mutation in ctDNA and oestrogen receptor-positive cancer were enrolled in cohort C...All 18 patients were evaluable; four (22% [95% CI 6–48]) patients had a confirmed partial response, and an additional four patients had unconfirmed partial responses...
Secondary therapy:
fulvestrant
DOI:
10.1016/S1470-2045(20)30444-7
Test:
